Amphastar reports Q1 adjusted EPS $1.04, consensus 77c

Reports Q revenue $171.84M, consensus $174.71M. Jack Zhang, Amphastar’s President and Chief Executive Officer, commented: “Amphastar’s strong first quarter results were led by BAQSIMI (R) revenue growth of 22% over what Eli Lilly & Company (“Lilly”) reported for the first quarter of 2023. This significant increase demonstrates a strong transition and the potential for continued growth of BAQSIMI.”